Interferon beta-1a-induced depression and suicidal ideation in multiple sclerosis

Lana-Peixoto, Marco Aurélio; Teixeira, Antônio Lúcio; Haase, Vítor Geraldi

doi:10.1590/s0004-282x2002000500007

Cited by 28 publications

(8 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, other serious mental complications are the occurrence of suicidal ideation, suicidal attempts, and completion (5)(6)(7)(8). Case reports worldwide have documented death by suicide in patients receiving cytokines as immune boosting therapy to treat a variety of diseases including melanoma, hepatitis C, HIV infections, and multiple sclerosis (5)(6)(7)(8)(9). While there is a growing recognition of the participation of cytokines in the etiology of mood disorders, their role as pro-suicidal factors has been less studied (10,11).…”

Section: Introductionmentioning

confidence: 99%

Elevated cytokine expression in the orbitofrontal cortex of victims of suicide

Tonelli

Stiller

Rujescu

et al. 2007

Acta Psychiatr Scand

215

138

View full text Add to dashboard Cite

Objective-Based on the reported association between cytokines with depression and suicide, and evidence of increased markers of inflammation in the brain of suicide victims, the present study examined the expression of cytokines in the orbitofrontal cortex of suicide victims.Method-In a postmortem sample obtained from the Brodman area 11 of suicides (n = 34) and controls (n = 17), real-time RT-PCR was used to compare the expression of mRNA species for tumor necrosis factor-a (TNF-α), interleukin (IL)-1β, 4, 5, 6, and 13.Results-Increased expression of IL-4 was found in women suicide victims and IL-13 in men suicide victims. Elevated but not significant cytokine expression was also observed for TNF-α in women suicide victims. • Limited information on psychiatric diagnoses and blood toxicology in the suicide group. Conclusion-To NIH Public Access

show abstract

Section: Introductionmentioning

confidence: 99%

Elevated cytokine expression in the orbitofrontal cortex of victims of suicide

Tonelli

Stiller

Rujescu

et al. 2007

Acta Psychiatr Scand

215

138

View full text Add to dashboard Cite

show abstract

“…Attributing all these changes exclusively to IFN treatment can be difficult because the conditions for which IFNs are prescribed are often themselves associated with neuropsychiatric symptom. 17 In contrast to many studies that show the effect of beta interferon in depression, 40 our study does not bring to light this effect.…”

Section: Mild Moderate Severementioning

confidence: 54%

Prevalence of depression among patients with multiple sclerosis in Erbil city

Sulaiman

Ali

2020

Zanco J. Med. Sci.

View full text Add to dashboard Cite

Multiple sclerosis (MS) is one of the central nervous system (CNS) diseases, which is chronic, inflammatory, and immune-mediated, typically presents in the third or fourth decade of life. 1,2 It is one of the most frequent nontraumatic disabling neurologic diseases, which affects 12,000 people in the United States alone per year. 3 There is high variability in the disease course. Its outcome is hard to predict, with no known cure. 4 Patients may be grouped into four categories; Relapsing-remitting (RR) MS, Secondary progressive (SP) MS, Primary progressive (PP) MS, and Progressive-relapsing (PR) MS, based on the course of the disease. 5 Nearly 87% of patients are of RRMS type, characterized by acute attacks (relapses) followed by partial or full recovery (remission). There are a heterogeneous group of symptoms, including changes in vision (unilateral visual loss, diplopia), weakness, incoordination, sensory loss or distortions, or changes in bowel and bladder function, cognitive change, fatigue, and mood disturbance. 6 Multifocal involvement of white and gray matter in the central nervous system can cause physical impairment and disability, with cognitive and psychological changes that often lessen patients' quality of life, occupational competence, and social interactions. 7 Psychiatric comorbidity is common in Background and objective: Multiple sclerosis is one of the chronic central nervous system diseases. Depression comorbidity is common with multiple sclerosis. This study aimed to determine the prevalence of depression among patients with multiple sclerosis and the relation of patient demographic data and disease status. Methods: A cross-sectional study was conducted in Rizgary Teaching Hospital in Erbil City, in a one-year duration from October 2017 to October 2018. The sample size was 169 known patients with multiple sclerosis, which was collected randomly. Beck Depression Inventory was used. The statistical package for the social sciences (version 25) was used for data analysis. Pearson Chi-square and Fisher's Exact Test were used to finding the association between various variables and depression. Results: The prevalence of depression among patients with multiple sclerosis was 53.5%. Age group more than 50 years was found more depressed (66.7 %,P = 0.006). Depression is more with those with multiple sclerosis for 10 years and more (84.6%) with a statistically significant association (P = 0.021). Treatment by rituximab show more depression (85.7%,P = 0.039). The frequency of severity of major depressive disorder was (mild 31.8%, moderate 52.9%, and severe 15.3%) and showed no significant association with different variables. Conclusion: The prevalence of depression among patients with multiple sclerosis was high. The age group of more than 50 years, duration of multiple sclerosis equal or more than 10 years, and rituximab treatment were regarded as risk factors.

show abstract

“…The mechanisms by which interferon beta causes depression are still unclear. A probable mechanism is a change in production of different types of cytokines [9]. An immune dysregulation has been recently associated with mood and cognitive changes in MS [4].…”

Section: Discussionmentioning

confidence: 99%

Suicide Attempts Following Fingolimod use in Patients with Relapsing Multiple Sclerosis: Is there a possible link?

2017

j of exper clin neur

View full text Add to dashboard Cite

Fingolimod is the first oral therapy approved for reduction of exacerbations in Multiple Sclerosis (MS). It is widely accepted that different preparations of beta interferons may aggravate depression and trigger suicide in MS patients and the drugs should be stopped immediately following suicidal idea. The association between newly approved drugs such as Fingolimod and Natalizumab with depression and suicidality is not clear. Here, we report three patients with relapsing MS, who committed suicide while receiving Fingolimod. Despite the fact that the link between suicide and Fingolimod is not clear, but practicing physicians need to be aware of this possible adverse event. It is also important to evaluate psychological status of the patients not only in patients receiving beta interferons, but also in patients who are treated with newly approved drugs.

show abstract

Interferon beta-1a-induced depression and suicidal ideation in multiple sclerosis

Cited by 28 publications

References 32 publications

Elevated cytokine expression in the orbitofrontal cortex of victims of suicide

Elevated cytokine expression in the orbitofrontal cortex of victims of suicide

Prevalence of depression among patients with multiple sclerosis in Erbil city

Suicide Attempts Following Fingolimod use in Patients with Relapsing Multiple Sclerosis: Is there a possible link?

Contact Info

Product

Resources

About